Recruiting

Mirikizumab

Sponsor:

University of North Carolina, Chapel Hill

Code:

NCT06696014

Conditions

Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC)

Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year?

Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.

Conditions

Ulcerative Colitis

Study ID

NCT06696014

Start date

May 8, 2025

Status verified date

Jul, 2025

Completion date

Jan, 2030

Anticipated

Primary completion date

Jan 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on mirikizumab therapy for moderate to severe UC or who plan to begin this therapy within the next 2 weeks. The start of the mirikizumab treatment must have been or be initiated in the setting of standard-of-care therapy.
  • Anticipation that the patient will be followed by the participating center for the next 12 months.
  • Diagnosis of UC must be established based on standard clinical, radiographic, endoscopic, and histologic criteria as described below.

Criteria for diagnosis of UC The following diagnostic criteria were developed by the NIDDK IBD Genetics Consortium and are provided as guidelines to complete documentation on individuals with Ulcerative Colitis.

A) Symptoms including one or more: diarrhea, rectal bleeding, abdominal pain, fever, extraintestinal manifestations, weight loss, or failure to thrive.

AND

B) Symptoms on two or more occasions separated by at least 8 weeks or ongoing symptoms of at least 6 weeks duration.

AND

C) Endoscopic Findings compatible with UC:

  • Superficial inflammation and/or ulceration (involving only the mucosa and submucosa) of the colon, which is continuous from the rectum extending proximally without skip lesions or complete rectal sparing (relative rectal sparing is allowed for patients receiving topical, rectal therapy; patchiness of endoscopic inflammation may be observed in patients with partially treated ulcerative colitis).
  • In patients with proctitis or left-sided ulcerative colitis, there may be an area of inflammation in the cecum, usually surrounding the appendiceal orifice.
  • No inflammation of the small intestine ("backwash ileitis" is allowed - non-stenotic superficial inflammation of the terminal ileal mucosa associated with severe pancolitis, which resolves following medical or surgical treatment of the colitis).
  • No features of Crohn's disease listed above. There is no minimum length of extension of UC required for inclusion in this study.

Exclusion Criteria:

Patients will be excluded if they meet any of the following criteria:

  • Inability to provide informed consent.
  • Non-English speaking.
  • Patients presenting for a one-time consultation.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • induction of clinical response as evaluated by the Simple Clinical Colitis Activity Index (SCCAI) for the patient-reported outcomes. [ Time Frame: Weeks 1,2,4,8,12,18,24,36, and 52 after the start of therapy (each time point will be assessed separately) ]

Central Contacts and Locations

Central contacts

Locations

South Denver Gastroenterology

Recruiting

Denver, Colorado, United States, 80113

Contacts

Principal Investigator:

Marcelo Kugelmas, MD

AdventHealth

Recruiting

Orlando, Florida, United States, 32804

Contacts

Principal Investigator:

Jennifer Seminerio-Diehl, MD

University of Iowa Health Care

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Principal Investigator:

Steven Polyak, MD

University of Louisville, Clinical Trials Unit

Recruiting

Louisville, Kentucky, United States, 40202

Contacts

Principal Investigator:

Gerald Dryden, M.D., Ph.D., MSPH, M.Sc.

University Of Rochester Medical Center

Recruiting

Rochester, New York, United States, 14642

Contacts

Principal Investigator:

Maisa Abdalla, MD, MPH

University of North Carolina

Recruiting

Chapel Hill, North Carolina, United States, 27599

Contacts

Principal Investigator:

Hans Herfarth, MD, PhD

Medical University of South Carolina (MUSC)

Recruiting

Charleston, South Carolina, United States, 29425

Contacts

Principal Investigator:

Erin Forster, MD, MPH

Southern Star Research Institute, LLC

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Principal Investigator:

Jeff Bullock, MC

TIDHI Innovation Inc.

Recruiting

Toronto, Ontario, Canada, M6A3B4

Contacts

Principal Investigator:

Mark Silverberg, MD, PhD

More Information

Sponsor

University of North Carolina, Chapel Hill

Last update posted

Jul 9, 2025

Last verified

Jul, 2025

Keywords

  • mirikizumab
  • Omvoh
  • MIRROR

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of North Carolina, Chapel Hill on 2025-07-09.